Universal Health Services stock has delivered a 25.7% total return over the past three years, yet the broader valuation checks still point to shares screening as cheap rather than fully priced in.

• Over the last three years, Universal Health Services has returned 25.7%, which suggests patient investors have been rewarded but not with an extreme move that would clearly exhaust upside potential.
• The planned acquisition of George Washington University Medical Faculty Associates may support longer term earnings power, while rising uninsured patient volumes and uncertainty around Medicaid supplemental payments can pressure profitability and weigh on what investors are willing to pay for the stock.
• Across Simply Wall St's broader yardstick, Universal Health Services comes through as undervalued in 5 of 6 checks, which points to a stock that still looks cheap on most measures even after its recent gains, according to the valuation score.

The issue now is whether Universal Health Services' current share price already reflects these mixed healthcare trends or still leaves room for further upside if the valuation gap closes.

Is Universal Health Services Still Cheap on Earnings?

The P/E ratio is a useful way to see what you are paying for each dollar of Universal Health Services earnings today. Universal Health Services currently trades at about 6.7x earnings, which is below the healthcare industry average of 24.9x and the broader peer group at 20.9x.

On Simply Wall St's fair multiple yardstick, a P/E of around 20.0x would be more in line with what you might expect for Universal Health Services given its profile. The gap between the current 6.7x and this reference ratio is wide, which is why the stock appears undervalued on this measure. Despite the recent cut to the 2026 profit outlook as uninsured patient volumes rise, the market is still pricing Universal Health Services at a notable discount to typical healthcare valuations.

On the P/E multiple, Universal Health Services stock currently looks undervalued compared with both this reference ratio and the wider healthcare sector.

The Universal Health Services Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Universal Health Services valuation gap leaves off and explain which future paths for growth, margins and earnings would correspond to a higher or lower share price than today. Each narrative links its numbers to a clear view on how Universal Health Services' growth, profitability and key risks might evolve. You can revisit these views as fresh results, guidance and policy updates come through on the Community page.

The Universal Health Services community currently splits between those who see a powerful behavioral health story and those focused on reimbursement and cost risks.

Bull case: 25% undervalued

“Organizations that can offer structured, evidence-based treatment at scale are becoming increasingly vital to the healthcare ecosystem…”

Bear case: roughly fairly valued

“Beginning in 2028, recent Medicaid legislation will sharply reduce Universal Health Services' supplemental payment benefits by approximately $360 million to $400 million annually by 2032, directly cutting into both net revenues and EBITDA growth and exposing the company to ongoing state-by-state policy uncertainty…”

Do you think there's more to the story for Universal Health Services? Head over to our Community to see what others are saying!

The Bottom Line

Universal Health Services still screens as undervalued on earnings, with the current P/E well below typical healthcare peers. The key question is whether that discount reflects temporary concern about reimbursement pressure and uninsured volumes or a more lasting reset in what investors are willing to pay for these cash flows. For now the crux of the debate is simple. Either profitability and policy risks ease enough for the multiple to move closer to sector norms, or the current valuation proves to be an accurate read on the long term risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.